Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
Insider trades, last 90 days
0 buys · 6 sells
- Sold $5.19M
- Open-market purchases (P) and sales (S), counted by Form 4 filing.
13F holders, Q2 2026
256
- +3 vs. Q1 2026
- Total value $3.04B
Superinvestors holding TARS
0
- None of the superinvestors held TARS at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by TARS insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 20264:22 PM ET | Sep 15, 2026 | LINK WILLIAM J PHDDirector | SSaleCommon Stock | −12.5K | $78.3796 | −$979.74K | 94.49K | −11.7% | SEC10b5-1 |
| Sep 9, 20264:14 PM ET | Sep 4, 2026 | Azamian Bobak R.President/CEO and Board Chair | SSaleCommon Stock | −10K | $90.56 | −$905.6K | 827.99K | −1.2% | SEC10b5-1 |
| Sep 9, 20264:13 PM ET | Sep 4, 2026 | Lin Elizabeth YeuChief Medical Officer | SSaleCommon Stock | −10.77K | $87.4998 | −$942.64K | 2.55K | −80.9% | SEC10b5-1 |
| Sep 9, 20264:13 PM ET | Sep 4, 2026 | Lin Elizabeth YeuChief Medical Officer | SSaleCommon Stock | −3.18K | $87.50 | −$278.25K | 1.59K | −66.7% | SEC10b5-1 |
| Sep 9, 20264:12 PM ET | Sep 4, 2026 | Neervannan SeshadriChief Operating Officer | SSaleCommon Stock | −4.56K | $85.00 | −$387.94K | 78.53K | −5.5% | SEC10b5-1 |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in TARS at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,856,137 | $242.71M | 0.00% | +303,525+8.5% | Added |
| Deep Track Capital, LP | 3,666,768 | $230.79M | 3.40% | +66,768+1.9% | Added |
| RTW INVESTMENTS, LP | 3,357,059 | $211.29M | 1.80% | +11,034+0.3% | Added |
| Jupiter Topco LLC | 2,808,796 | $176.83M | 0.07% | +2,808,796 | New |
| Paradigm Biocapital Advisors LP | 2,775,649 | $174.7M | 3.27% | +213,495+8.3% | Added |